Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Evidence-Base for Jin Kyung Seok's Scientific Strength

The clearest signal of rigorous, mechanistic science comes from the AML stem-cell work: JQ1 resistance in CD34+CD38- leukemic stem cells was traced to AMPK/ULK1-dependent prosurvival autophagy, using 13 primary patient samples (7 JQ1-sensitive, 6 resistant), siRNA knockdowns, compound C pharmacology, and TEM/confocal validation of autophagy flux. This is a well-controlled, mechanistically deep study that was later conceptually extended to FLT3-ITD AML via ULK1 inhibition AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells [2017] ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia [2020].

Translational imaging work shows methodological competence: a site-specific 89Zr-labeled anti-PD-1 immuno-PET tracer achieved 70% labeling efficiency, 98% radiochemical purity, biexponential clearance (T1/2β 15.09 h), and PET uptake correlated with tumor PD-1 levels (r=0.771, P<0.001), though the EL4 murine model and PMA (a non-physiological activator) limit translational reach 89Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFκB and JNK Signaling [2022]. Similarly, a FDG-PET radiogenomics study linked radiomic features to oncogenic pathways in 137 lung-cancer patients, but acknowledged heterogeneous multi-center data, limited validation, and small subtype-specific samples Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations [2020].

The portfolio also contains lower-rigor or narrower clinical/observational work: a retrospective single-center lamivudine prophylaxis study (N=169, no randomization, older HBV DNA assays) Updated Longitudinal Data on Acute Exacerbation of Chronic Hepatitis B in Patients With Breast Cancer Receiving Anthracycline-based Adjuvant Chemotherapy [2011], a retrospective gastric dysplasia/carcinoma ESD series Early-stage gastric cancers represented as dysplasia in a previous forceps biopsy: The importance of clinical management [2013], and an industry-sponsored randomized trial (teneligliptin vs sitagliptin, N=201) where funding by Handok Inc. introduces sponsor-bias risk despite non-inferiority results Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride [2018].

Citation Metrics and Identity Caveats

Metrics conflict across databases: the Semantic Scholar-style record reports h-index 12, 412 citations, 35 papers, whereas OpenAlex lists h-index 21, 1,528 citations, 37 works OpenAlex author record A5017576057 [2026]. This gap likely reflects indexing of differently authored-name variants or consortium papers, a known blindspot. Notably, the supplied paper titles (MSC/ovarian/placenta biology, trophoblast invasion, PCOS) do not overlap with the 16 full-text evidence records (AML, PET imaging, ceramics, hepatitis B, orthopedics), so the actual first/senior-authorship contribution of this individual is uncertain — the h-index 21 figure may substantially overstate personal scientific output if co-authorship inflation is present.

What would change this assessment: identification of a separate co-author named "Jin Kyung Seok" in the non-omics papers, ORCID-disambiguated full publication list, and independent replication of the AML autophagy-resistance mechanism in vivo would materially raise or lower the confidence in this review.

 BGPT Author Review

Scientific Quality

Mid-tier biomedical researcher. The AML autophagy-resistance work is genuinely strong mechanistic science with patient-derived validation; imaging and ceramics work show breadth. However, the aggregate citation metrics are inflated by likely name-collision/co-authorship ambiguity (h-index 12 vs 21 across databases), several supplied papers have weak designs (retrospective single-center, small N), and the author's core independent contribution is hard to isolate. No first-author landmark impact yet.

Communication Quality

Papers report methods and limitations reasonably clearly, with quantitative detail where appropriate (PK parameters, effect sizes, FDR thresholds). However, communication is conventional and dense; some papers (TMTH alopecia, scriptaid iSCNT) omit exact sample sizes, and the radiogenomics paper reports many exploratory associations without concise takeaways, burdening the reader.

Author Novelty

The AMPK/ULK1 autophagy resistance mechanism in AML stem cells and the ULK1-inhibitor FLT3-ITD strategy were early, timely contributions to a growing field rather than paradigm shifts. The 89Zr PD-1 immuno-PET and Y2O3-MgO two-step sintering work are moderately novel applications. Clinical and observational papers are incremental. Overall solid but not groundbreaking.

Scientific Rigor

Strengths: mechanistic controls (siRNA, pharmacological inhibitors, TEM, rescue experiments), explicit limitation statements, and reasonable statistical methods in several papers. Weaknesses: absence of in vivo validation in key mechanistic papers, small patient samples (n=13 primary AML, n=46 AE-CHB), lenient significance thresholds in the microarray work (P≤0.07), sponsor involvement in the diabetes trial, and retrospective designs in several clinical studies. Per-protocol-only efficacy analysis in the trial is a bias risk.